Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2– Advanced Breast Cancer

With more than 6 years of follow-up in the phase III PALOMA-3 trial, the addition of palbociclib to fulvestrant maintained a significant survival benefit compared with fulvestrant alone in patients with HR-positive, HER2-negative advanced breast cancer that progressed on prior endocrine therapy.